<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31759">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870518</url>
  </required_header>
  <id_info>
    <org_study_id>13BN006</org_study_id>
    <nct_id>NCT01870518</nct_id>
  </id_info>
  <brief_title>Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI</brief_title>
  <acronym>DBS</acronym>
  <official_title>Neurocognitive Effects of Bilateral Subthalamic Nucleus Versus Globus Pallidus Interna Deep Brain Stimulation in Parkinson's Disease Patients With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Joseph's Hospital and Medical Center, Phoenix</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: This is a prospective single-center, randomized, patient and evaluator-blind
      clinical trial to compare the neurocognitive outcomes of globus pallidus interna (GPi)
      versus subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD)
      patients with mild cognitive impairment (MCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deep brain stimulation (DBS) of the globus pallidus interna (GPi) or subthalamic nucleus
      (STN) has been accepted as the surgical treatment of choice for patients with advanced
      Parkinson's Disease (PD), demonstrating improvements in motor function that exceed those
      achieved by medical management alone. Unfortunately, a paucity of data exist comparing
      non-motor outcomes between DBS of the available targets. Specifically, a high prevalence of
      concurrent cognitive dysfunction or early dementia exists in PD patients, and it is unclear
      whether DBS target selection may have differential effects with regards to cognitive
      outcomes in PD patients with early evidence of mild cognitive impairment Previous studies
      indicate that stimulation of either the GPi or STN is associated with decrements in
      patients' verbal fluency, visuospatial memory, as well as overall cognitive decline, but
      those patients were randomized without consideration for baseline neurocognitive performance
      and it is unclear whether these effects are due to treatment or rather the natural history
      of these patients.

      In addition to the clinical arm of this trial, another secondary goal is to evaluate several
      biomarkers obtained from blood and cerebrospinal in order to determine their utility if any
      as prognosticators of patient cognitive and motor outcomes. Specifically, we will be
      evaluating levels of amyloid 1-42, total tau, phosphorylated tau 181, and brain derived
      neurotrophic factor in the cerebrospinal fluid as well as genotyping the apolipoprotein-E
      gene. These proteins and genotypes are still currently under investigation as potential
      biomarkers for dementia as well as neuroplasticity.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Neurocognitive Function</measure>
    <time_frame>6 months post-operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>By focusing on patients with MCI, our primary aim will be to detect whether STN or GPi DBS incur target specific impacts on patients' subsequent neurocognitive function.Patients will undergo neuropsychological testing pre-operatively and again at six months post-operatively. Patient's will also undergo a Montreal Cognitive Assessment at specified intervals: pre-operatively, 3weeks, 6 weeks and 6 months post-operatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional motor improvements</measure>
    <time_frame>6 month post-operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary aim will be measure functional motor outcomes in our patients.Patient's will undergo Unified Parkinson's Disease Rating Scale (UPDRS 3 and 4) motor testing pre-operatively in the off medication and on medication states. Patients will be re-tested 6 months post-operatively in the following states: on device / off medication, off device / off medication, on device / on medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Parkinson's patients with MCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: deep brain stimulation surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's patients without MCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: deep brain stimulation surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilateral GPi DBS</intervention_name>
    <arm_group_label>Parkinson's patients with MCI</arm_group_label>
    <arm_group_label>Parkinson's patients without MCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilateral STN DBS</intervention_name>
    <arm_group_label>Parkinson's patients with MCI</arm_group_label>
    <arm_group_label>Parkinson's patients without MCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of idiopathic Parkinson's disease

          -  deemed an appropriate candidate for DBS surgery

          -  Montreal Cognitive Assessment (MoCA) score &lt; 25

          -  Neuropsychological testing with the diagnosis of Mild Cognitive Impairment

        Exclusion Criteria:

          -  no diagnosis of Parkinson's disease

          -  not appropriate for DBS surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco A Ponce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Neurological Institute / St. Joseph's Hospital &amp; Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute / St. Joseph's Hospital &amp; Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012 Jul 3;79(1):55-65. doi: 10.1212/WNL.0b013e31825dcdc1. Epub 2012 Jun 20.</citation>
    <PMID>22722632</PMID>
  </reference>
  <reference>
    <citation>Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005 Oct;20(10):1255-63. Review.</citation>
    <PMID>16041803</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A, Volkmann J, Hariz MI, Quinn NP, Speelman JD, Guridi J, Zamarbide I, Gironell A, Molet J, Pascual-Sedano B, Pidoux B, Bonnet AM, Agid Y, Xie J, Benabid AL, Lozano AM, Saint-Cyr J, Romito L, Contarino MF, Scerrati M, Fraix V, Van Blercom N. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain. 2005 Oct;128(Pt 10):2240-9. Epub 2005 Jun 23.</citation>
    <PMID>15975946</PMID>
  </reference>
  <reference>
    <citation>Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010 Jun 3;362(22):2077-91. doi: 10.1056/NEJMoa0907083.</citation>
    <PMID>20519680</PMID>
  </reference>
  <reference>
    <citation>Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998 Feb 19;338(8):506-11. Erratum in: N Engl J Med 1998 Apr 30;338(18):1325.</citation>
    <PMID>9468467</PMID>
  </reference>
  <reference>
    <citation>Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging. 2009 Feb;30(2):165-73. Epub 2007 Jul 23.</citation>
    <PMID>17646035</PMID>
  </reference>
  <reference>
    <citation>Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013 Jan;14(1):7-23. doi: 10.1038/nrn3379. Review.</citation>
    <PMID>23254191</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 3, 2013</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Dementia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
